Delcath Systems Stock Gains on Positive CHEMOSAT Melanoma Data [Yahoo! Finance]
Delcath Systems, Inc. (DCTH)
US:NASDAQ Investor Relations:
delcath.com/investors
Company Research
Source: Yahoo! Finance
The study, conducted by researchers at the University of Tübingen, Germany, demonstrates that Delcath's CHEMOSAT Hepatic Delivery System significantly improves melanoma-specific survival (MSS) in patients with liver metastases from uveal melanoma when used as a first-line therapy. This retrospective study analyzed 167 patients diagnosed between 2005 and 2021 and found that those receiving liver-directed therapies, including CHEMOSAT, had notably better survival outcomes than those treated with systemic therapies. Delcath Systems specializes in interventional oncology, particularly for primary and metastatic liver cancers. Its key products include HEPZATO KIT and CHEMOSAT Hepatic Delivery System. In Europe, the CHEMOSAT device is used for similar purposes but regulated as a Class III medical device. Shares of DCTH were up 2% in pre-market trading following the news last Friday. Significance of Delcath Systems' CHEMOSAT Per Delcath Systems, this study underscores the vital rol
Show less
Read more
Impact Snapshot
Event Time:
DCTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DCTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DCTH alerts
High impacting Delcath Systems, Inc. news events
Weekly update
A roundup of the hottest topics
DCTH
News
- Delcath Systems, Inc. (NASDAQ: DCTH) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Delcath Systems, Inc. (NASDAQ: DCTH) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO KIT™ in Metastatic Uveal Melanoma SubgroupsBusiness Wire
- Delcath Systems, Inc. (NASDAQ: DCTH) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
DCTH
Earnings
- 8/5/24 - Miss
DCTH
Sec Filings
- 9/26/24 - Form 424B3
- 9/26/24 - Form 424B3
- 9/26/24 - Form EFFECT
- DCTH's page on the SEC website